Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.

NCT Number	NCT06922669
Lead Sponsor	General Hospital of Shenyang Military Region
Conditions	Drug Induced Liver Injury
Enrollment	232 participants
Start Date	2025-06-24
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-18